Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: what do we know and future vistas

Expert Opinion on Drug Safety, Journal Year: 2024, Volume and Issue: 23(5), P. 539 - 542

Published: March 23, 2024

KEYWORDS: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs)liraglutidesemaglutidetirzepatideweight lossobesityoverweightdiabetesdepressionsuicide

Language: Английский

---

Efficacy, safety, and tolerability of xanomeline for schizophrenia spectrum disorders: a systematic review

Expert Opinion on Pharmacotherapy, Journal Year: 2024, Volume and Issue: 25(4), P. 467 - 476

Published: March 3, 2024

Introduction We systematically reviewed extant studies evaluating the efficacy and tolerability of xanomeline xanomeline-trospium (KarXT) for treatment adults with schizophrenia.

Language: Английский

---

Glucagon-like peptide 1 agonist and effects on reward behaviour: A systematic review

Physiology & Behavior, Journal Year: 2024, Volume and Issue: 283, P. 114622 - 114622

Published: June 28, 2024

The roles of metabolic signals, including Glucagon-like peptide 1 (GLP-1), have been implicated in multiple domains outside regulation. There is a growing interest repurposing receptor agonists (GLP-1RAs) as therapeutics for motivation and reward-related behavioural disturbances. Herein, we aim to systematically review the extant evidence on potential effects GLP-1RAs reward system.

Language: Английский

---

Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression

European Neuropsychopharmacology, Journal Year: 2024, Volume and Issue: 85, P. 58 - 65

Published: July 1, 2024

In ESCAPE-TRD (NCT04338321), esketamine nasal spray (NS) significantly increased the probability of remission at Week 8, and being relapse-free through 32 after versus quetiapine extended release (XR) in patients with treatment resistant depression (TRD). Here, we explore time course, burden consequences emergent adverse events (TEAEs) phase IIIb ESCAPE‑TRD trial. Patients TRD were randomised 1:1 to NS or XR, dosed per label alongside an ongoing selective serotonin reuptake inhibitor/serotonin norepinephrine inhibitor. this secondary publication, safety analyses (comprising who received ≥1 dose study treatment) included incidence, severity durations (Kaplan‑Meier method) TEAEs, subsequent dispositional changes. P values not adjusted for multiple testing. 336 340 XR; 334 treatment, respectively. TEAEs more common than XR (91.9 % 78.0 %; p < 0.001), but typically mild/moderate transient nature: a greater proportion resolved on same-day (92.0 12.1 %) lead discontinuation fewer (4.2 11.0 %, respectively; 0.001). The days spent was lower (median: 11.9 21.3 Although frequent NS, mild, less likely XR. Data consistent established profiles, no new signals identified. Alongside efficacy, demonstrably favourable tolerability profile further supports its use TRD.

Language: Английский

---

Pharmacological Treatment of Binge Eating Disorder and Frequent Comorbid Diseases

CNS Drugs, Journal Year: 2024, Volume and Issue: 38(9), P. 697 - 718

Published: Aug. 3, 2024

Language: Английский

---

The Co-occurrence of Depression and Obesity

The Journal of Clinical Psychiatry, Journal Year: 2024, Volume and Issue: 85(2)

Published: June 3, 2024

Language: Английский

---

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: A replication study using reports to the World Health Organization pharmacovigilance database (VigiBase®)

Journal of Affective Disorders, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 1, 2024

Language: Английский

---

Consensus on the key characteristics of metabolism disruptors

Nature Reviews Endocrinology, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 29, 2024

Language: Английский

---

Metformin for the Prevention of Antipsychotic-Induced Weight Gain: Guideline Development and Consensus Validation

Schizophrenia Bulletin, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 9, 2024

Overweight and obesity are highly prevalent in people with severe mental illness (SMI). Antipsychotic-induced weight gain (AIWG) is one of the most commonly reported distressing side effects treatment living SMI place a high value on avoidance this effect. Metformin effective pharmacological intervention studied for prevention AIWG yet clear guidelines lacking evidence has not translated into practice. The aim research was to develop guideline use metformin AIWG.

Language: Английский

---

Pharmacotherapy of Weight‐loss and Obesity with a Focus on GLP 1‐Receptor Agonists

The Journal of Clinical Pharmacology, Journal Year: 2024, Volume and Issue: 64(10), P. 1204 - 1221

Published: June 26, 2024

Obesity is a disease of epidemic proportions in the United States and contributes to morbidity mortality for large part population. In addition, financial costs this society are high. Lifestyle modifications key prevention treatment but adherence long-term success have been challenging. Bariatric surgery has available pharmacologic approaches, first developed 1950s, continue be an option; however, existing formulations not provided optimal clinical efficacy had many concerning adverse effects. Over last decade, glucagon-like peptide-1 (GLP-1) receptor agonists, novel group medications type 2 diabetes, were found produce significant weight loss. Several formulations, at higher doses, received FDA approval obesity or those overweight with weight-related co-morbidities. More hormone-based therapies being developed, some dual triple-receptor agonist activity. Their use, without questions concerns as safety efficacy, problems cost reimbursement, how their use may intersect public health efforts manage epidemic. This review will focus on GLP-1 agonists currently used loss discuss pharmacology, pertinent research findings establishing benefits risks, issues prescribing these medications, perspective from point view.

Language: Английский

---